|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||302.00 - 306.83|
|52-week range||298.00 - 430.00|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||16.14|
|Forward dividend & yield||9.97 (3.24%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||N/A|
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry's years-long pandemic boost is ebbing. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the Swiss pharmaceuticals and diagnostics company said in a statement. COVID-related sales, mainly from lab testing and antibody treatment Ronapreve, are seen falling by 5 billion Swiss francs ($5.5 billion) for the full year, it said.
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.